You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 10,279,036


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,279,036
Title:Antibody-albumin nanoparticle complexes comprising albumin, bevacizumab, and paclitaxel, and methods of making and using the same
Abstract: This invention relates to antibody-albumin nanoparticle complexes comprising albumin, bevacizumab, and paclitaxel, wherein the nanoparticle complex has been pre-formed in vitro such that the nanoparticle complex has antigen-binding specificity (e.g., VEGF binding specificity), for the purpose of providing cancer (e.g., VEGF-related cancer) treatments in a subject in need thereof.
Inventor(s): Markovic; Svetomir N. (Rochester, MN), Nevala; Wendy K. (Rochester, MN)
Assignee: Mayo Foundation for Medical Education and Research (Rochester, MN)
Application Number:15/413,257
Patent Claims:1. An antibody-albumin nanoparticle complex comprising albumin, an antibody with binding specificity for vascular endothelial growth factor (VEGF), and paclitaxel, wherein the nanoparticle complex has been pre-formed in vitro by mixing an aqueous albumin-paclitaxel nanoparticle with the antibody under conditions to form the nanoparticle complex, such that the nanoparticle complex has VEGF binding specificity, wherein the antibody is bevacizumab, and wherein the diameter of said complex is between 0.1 .mu.m and 1 .mu.m.

2. The antibody-albumin nanoparticle complex of claim 1, said complex having a diameter of between 0.1 .mu.m and 0.9 .mu.m.

3. The antibody-albumin nanoparticle complex of claim 1, said complex having a diameter of between 0.1 .mu.m and 0.3 .mu.m.

4. The antibody-albumin nanoparticle complex of claim 1, wherein the ratio of albumin-paclitaxel nanoparticle to antibody is between 5:1 and 1:2.5.

5. A method of making an antibody-albumin nanoparticle complex, the method comprising mixing an aqueous albumin-paclitaxel nanoparticle with an antibody with binding specificity for vascular endothelial growth factor (VEGF) in vitro under conditions to form the nanoparticle complex, wherein the antibody is bevacizumab, and wherein the diameter of said complex is between 0.1 .mu.m and 1 .mu.m.

6. The method of claim 5, wherein the diameter of said complex is between 0.1 .mu.m and 0.9 .mu.m.

7. The method of claim 5, wherein the ratio of albumin-paclitaxel nanoparticle to antibody is between 5:1 and 1:2.5.

8. The method of claim 7, wherein the ratio is about 5:1.

9. The method of claim 5, wherein the aqueous albumin-paclitaxel nanoparticle is incubated with the antibody at an incubation temperature of between 15.degree. C. and 30.degree. C.

10. The method of claim 5, wherein the aqueous albumin-paclitaxel nanoparticle is incubated with the antibody for between about 5 minutes and about 60 minutes.

11. The method of claim 5, wherein the aqueous albumin-paclitaxel nanoparticle is incubated with the antibody for between about 20 minutes and about 400 minutes.

12. A method of making a pharmaceutical composition comprising a pharmaceutically acceptable carrier and antibody-albumin nanoparticle complexes, the method comprising mixing aqueous albumin-paclitaxel nanoparticles with an antibody with binding specificity for vascular endothelial growth factor (VEGF) in vitro under conditions to form the nanoparticle complexes, and adding the pharmaceutically acceptable carrier to the nanoparticle complexes, wherein the antibody is bevacizumab, and wherein the average diameter of said complexes is between 0.1 .mu.m and 1 .mu.m.

13. The method of claim 12, wherein the ratio of albumin-paclitaxel nanoparticle to antibody is between 5:1 and 1:2.5.

14. The method of claim 13, wherein the ratio is about 5:1.

15. The method of claim 12, wherein the aqueous albumin-paclitaxel nanoparticle is incubated with the antibody at an incubation temperature of between 15.degree. C. and 30.degree. C.

16. The method of claim 12, wherein the aqueous albumin-paclitaxel nanoparticle is incubated with the antibody for between about 5 minutes and about 60 minutes.

17. The method of claim 12, wherein the aqueous albumin-paclitaxel nanoparticle is incubated with the antibody for between about 20 minutes and about 400 minutes.

18. The method of claim 12, wherein the pharmaceutically acceptable carrier is saline, water, lactic acid, mannitol, or a combination thereof.

19. The method of claim 12, wherein the pharmaceutical composition is formulated for injection into a patient.

20. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and antibody-albumin nanoparticle complexes, said nanoparticle complexes comprising albumin, a bevacizumab antibody, and paclitaxel, wherein the nanoparticle complexes have been pre-formed in vitro by mixing aqueous albumin-paclitaxel nanoparticles with the antibody under conditions to form the nanoparticle complexes, such that the nanoparticle complexes have VEGF binding specificity, and wherein the average diameter of greater than 60% of said complexes is between 0.1 .mu.m and 0.95 .mu.m.

21. The pharmaceutical composition of claim 20, wherein the average diameter of greater than 60% of said complexes is between 0.1 .mu.m and 0.9 .mu.m.

22. The pharmaceutical composition of claim 20, wherein the average diameter of greater than 60% of said complexes is between 0.1 .mu.m and 0.3 .mu.m.

23. The pharmaceutical composition of claim 20, wherein the ratio of albumin-paclitaxel nanoparticle to antibody is between 5:1 and 1:2.5.

24. The pharmaceutical composition of claim 20 is formulated for injection.

25. The pharmaceutical composition of claim 20, wherein the pharmaceutically acceptable carrier is saline, water, lactic acid, mannitol, or a combination thereof.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.